Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of December 2019, with a specific transaction date of December 16, 2019. The report serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) under the GlaxoSmithKline Deferred Investment Award programme.
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics for the company. It details a specific executive compensation event:
- Executive: Mr. R Simard, President, Pharmaceuticals Supply Chain.
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Type: Final vesting of an award made on December 13, 2013.
- Volume: 3,414.453 notional Ordinary Shares.
- Price: £17.642 per share.
- Value: Gross cash payment of £60,237.79 (subject to applicable tax withholding).
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It solely documents the settlement of a deferred investment award for a specific executive.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies related to the company's business outlook. It is a statutory disclosure of a specific equity-related transaction.
Key Facts for Investor Verification
- Verify the vesting schedule and terms of the GlaxoSmithKline Deferred Investment Award programme.
- Confirm the tax withholding implications for the £60,237.79 gross payment to Mr. Simard.
- Note that this filing does not reflect broader company performance or financial results for the period.